Scaling Liquid Biopsy Innovation Across the Middle East with MSK-ACCESS™ powered with SOPHiA DDM™

Date: June 10, 2026 - June 10, 2026
Type: Virtual
Location: EMEA
Areas of Interest: Liquid Biopsy

10 June 2026 I 15:00 - 17:00 GST | 7:00 - 9:00 EDT

Join us for an exclusive virtual event bringing together leading oncology experts, healthcare decision-makers, pharmaceutical partners, policy representatives, and key opinion leaders from across the Middle East region.

This high-level session will explore the future of precision medicine and the evolving role of liquid biopsy in transforming cancer care delivery and genomic testing strategies.

At the center of the discussion is the collaboration between SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center, showcasing the successful decentralization of MSK’s renowned genomic assay, MSK-ACCESS™, powered with SOPHiA DDM™ for liquid biopsy applications.

The event will also feature real-world implementation examples and regional perspectives from our local users at M42, an Abu Dhabi-based global healthcare leader, highlighting innovation, scalability, and impact in precision oncology.

Meet our world class line-up of speakers

Dr. Ghassan Abou Alfa, MD, MBA, PhD
Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center

Dr. Val Zvereff
Laboratory Director, M42 Biogenix

Dr. Azza Attia
Clinical Geneticist, M42

Dr. Lina Li, MBA
Product Director Solid Tumors & Liquid Biopsy, SOPHiA GENETICS

Dr. Massimo Cerfeda
Regional Director South & East Europe, SOPHiA GENETICS

Register Now

Facebook

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services